Piggybacking and IOL is a successful technique

Article

Piggybacking with the Add-On IOL is safe, efficient and reliable for correcting pseudophakic refractive errors.

Piggybacking with the Add-On IOL is safe, efficient and reliable for correcting pseudophakic refractive errors.

A team led by Dr B. Basarir, Beyoglu Eye Education and Research Hospital, Istanbul, Turkey, included 10 eyes of 10 patients with pseudophakic refractive errors. All patients were targeted to achieve a range of refraction between -0.50 to +0.50 D.

Preoperative and postoperative outcome measures included uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), endothelial cell count (ECC), anterior chamber depth (ACD), the distance between intraocular lenses and contrast sensitivity measurements under mesopic, scotopic, and scotopic with glare conditions.

The mean preoperative and postoperative UDVA was 0.133±0.12 and 0.73±0.27, respectively. Mean preoperative and postoperative CDVA were 0.77±0.26 and 0.79±0.27, respectively.

The findings revealed the mean preoperative and postoperative ACD to be 3.87±0.91 mm vs. 3.58±1.05 mm, respectively. All patients achieved the target refractive range of -0.50 D to +0.50 D and no complications were recorded.

The abstract, recently published in the European Journal of Ophthalmology can be found here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.